Immunome Overview
- Year Founded
-
2006
- Status
-
Public
- Employees
-
177
- Stock Symbol
-
IMNM
- Investments
-
3
- Share Price
-
$18.77
- (As of Friday Closing)
Immunome General Information
Description
Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.
Contact Information
Website
www.immunome.comCorporate Office
- 18702 North Creek Parkway
- Suite 100
- Bothell, WA 98011
- United States
Corporate Office
- 18702 North Creek Parkway
- Suite 100
- Bothell, WA 98011
- United States
Immunome Timeline
Immunome Stock Performance
As of 13-Nov-2026, Immunome’s stock price is $18.77. Its current market cap is $2.22B with 118M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $18.77 | $18.70 | $16.11 - $30.06 | $2.22B | 118M | 1.37M | -$2.63 |
Immunome Financials Summary
As of 30-Sep-2026, Immunome has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 1,927,799 | 2,161,386 | 425,458 | 366,939 |
| Revenue | 0 | 6,941 | 9,041 | 14,018 |
| EBITDA | (296,934) | (221,158) | (303,698) | (108,802) |
| Net Income | (282,649) | (212,394) | (292,963) | (106,806) |
| Total Assets | 505,527 | 683,188 | 240,241 | 148,540 |
| Total Debt | 11,385 | 3,855 | 4,832 | 1,650 |
Immunome Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Immunome Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Immunome Comparisons
Industry
Financing
Details
Immunome Competitors (70)
One of Immunome’s 70 competitors is Aura Biosciences, a Formerly VC-backed company based in Boston, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Aura Biosciences | Formerly VC-backed | Boston, MA | ||||
| BeOne Medicines | Formerly PE-Backed | Beijing, China | ||||
| BioAtla | Formerly VC-backed | San Diego, CA | ||||
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| ADC Therapeutics | Formerly VC-backed | Epalinges, Switzerland |
Immunome Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Immunome Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Immunome Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Immunome Investments & Acquisitions (3)
Immunome’s most recent deal was a Corporate Asset Purchase with Atreca (Antibody-related Assets and Materials) for . The deal was made on 17-May-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Atreca (Antibody-related Assets and Materials) | 17-May-2024 | Corporate Asset Purchase | Buildings and Property | ||
| Ayala Pharmaceuticals (AL102 and AL101 in Wilmington, Delaware) | 25-Mar-2024 | Corporate Asset Purchase | Buildings and Property | ||
| Immunome (acquired in 2023) | 03-Oct-2023 | Merger/Acquisition | Drug Discovery |
Immunome ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
36.81 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Immunome Exits (1)
Immunome’s most recent exit was on 03-Oct-2023 from Immunome (acquired in 2023). The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Immunome (acquired in 2023) | 03-Oct-2023 | Completed |
|
Immunome FAQs
-
When was Immunome founded?
Immunome was founded in 2006.
-
Where is Immunome headquartered?
Immunome is headquartered in Bothell, WA.
-
What is the size of Immunome?
Immunome has 177 total employees.
-
What industry is Immunome in?
Immunome’s primary industry is Pharmaceuticals.
-
Is Immunome a private or public company?
Immunome is a Public company.
-
What is Immunome’s stock symbol?
The ticker symbol for Immunome is IMNM.
-
What is the current stock price of Immunome?
As of 13-Nov-2026 the stock price of Immunome is $18.77.
-
What is the current market cap of Immunome?
The current market capitalization of Immunome is $2.22B.
-
Who are Immunome’s competitors?
Aura Biosciences, BeOne Medicines, BioAtla, Alnylam Pharmaceuticals, and ADC Therapeutics are some of the 70 competitors of Immunome.
-
What is Immunome’s annual earnings per share (EPS)?
Immunome’s EPS for 12 months was -$2.63.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
